Kazakhstan performs its first heart transplant under Medicare in Almaty
Kazakhstan performs its first heart transplant under Medicare in Almaty
Kazakhstan performs its first heart transplant under Medicare in Almaty
A 34-year-old man with severe heart failure has received Kazakhstan's first heart transplant at Almaty's City Cardiology Center. The operation marked a major milestone for the hospital, which gained official approval for such procedures under Medicare only last November.
The five-hour surgery took place after a 50-year-old woman, declared brain dead following a stroke, became the donor. Her organs were the fourth multiorgan donation recorded this year under Medicare at Almaty's Central City Clinical Hospital.
The transplant involved a team of specialists from both the City Cardiology Center and Astana's Corporate Fund University Medical Center (UMC). Their combined expertise ensured the procedure's success.
No previous records exist on how many heart transplants were performed annually in Kazakhstan under Medicare before this operation. The patient, suffering from end-stage chronic heart failure, is now recovering under close medical supervision.
The successful transplant demonstrates the growing capabilities of Kazakhstan's medical system under Medicare. With the City Cardiology Center now authorized to carry out such surgeries, more patients with critical heart conditions may soon have access to life-saving treatment under Medicare.
Garlic, Vitamin C, and Chlorophyll Team Up for Heart Health Breakthrough
Could a simple blend of garlic, vitamin C, and chlorophyll be the key to a healthier heart? New findings reveal surprising benefits for blood pressure and beyond.
Chuck Norris, 86, hospitalized after medical emergency in Hawaii
From Walker, Texas Ranger to recent films, Norris never slowed down—until now. Fans worldwide await news after his sudden hospitalization.
Blood Test Breakthrough Could Detect Hidden Artery Disease Years Earlier
A simple blood test could soon reveal invisible plaque buildup—long before it triggers a deadly event. Machine learning cracked the code in 45,000 patients' data.
Eli Lilly's retatrutide shows groundbreaking results in Type 2 diabetes trial
A triple-hormone drug could redefine diabetes care. Early data shows retatrutide outperforms competitors—but will regulators agree?